Shlobby Posted - 1 week ago

$JSPR looks really good

FIREINSP Posted - 1 week ago

@LoyalDog My portfolio I have had 4 in the past year...Only one has made money after the split. $JSPR

skyrockets_Inc Posted - 10/29/24

$JSPR LR-MDS data has to be aby day now. IR confirmed to me via email this is still on track for 2H2024

skyrockets_Inc Posted - 10/28/24

$JSPR seems like a good takeover target

briefingcom Posted - 10/23/24

$JSPR: Jasper Therapeutics announces that it is commencing an open-label extension study in chronic urticarias that will roll over patients from the BEACON and SPOTLIGHT studies upon completion of their initial follow up period https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241023080634JSPR&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

TheTradeXchange Posted - 10/23/24

$JSPR - Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria

SHILL1104 Posted - 1 month ago

$JSPR

Bromberger Posted - 1 month ago

$JSPR What is wrong with this stock ?

_www_larval_com_ Posted - 1 month ago

$JSPR has turned -4% lower to 8% (~1Mv) a moment ago, 10/18 options, follow for more volatility.

Bromberger Posted - 1 month ago

$JSPR

CopyTradeStocks Posted - 1 month ago

$JSPR Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria. BUT I DO not think that will close the day up. probably will be a daily red candle

ClassifiedTrades Posted - 1 month ago

$JSPR hitting 2nd target. $VERB

_www_larval_com_ Posted - 1 month ago

$LFMD 5%[8%] $JSPR 5%[18%] $ZENA 5%[-6%] $SSSS -4%[1%] $LASE -4%[3%] most notable movement within the first minutes of trading.

thetechtrader Posted - 1 month ago

$JSPR spiked 4 to 19, wedged at 17.50, then popped, wedged, popped. Extension targets are 20.75 & 22+ Support near 16.80-17. #technicaltrading #daytrade #tradealert #marketrecap #stockstowatch #stockstobuy

briefingcom Posted - 1 month ago

$JSPR: Jasper Therapeutics reports preliminary data from the Company’s ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with cold urticaria or symptomatic dermographism, the two most prevalent sub types of CIndU https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241014071610JSPR&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

DonCorleone77 Posted - 1 month ago

$LBPH $SOFI $RILY $JSPR $CAT Please feel free to follow me for pre-market and after-hours movers every day. PRE-MARKET MOVERS: Currently Higher: -- Longboard Pharmaceuticals (LBPH) up 51.5% after H. Lundbeck A/S announced an agreement for Lundbeck to acquire Longboard for $60.00 per share in cash -- B. Riley Financial (RILY) up 18.0% after B. Riley Financial and funds managed by Oaktree Capital Management, have signed a definitive agreement to establish a partnership in Great American Holdings, a newly formed holding company -- SoFi Technologies (SOFI) up 8.3% SoFi Technologies after entering $2B loan agreement with Fortress Investment -- Flutter Entertainment (FLUT) up 5.8% after Wells Fargo upgraded the stock to Overweight from Equal Weight with a price target of $295, up from $224, implying 34% upside -- Jasper Therapeutics (JSPR) up 5.7% after reporting preliminary data from the company's ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with cold urticaria or symptomatic dermographism -- Western Digital (WDC) up 2.3% after announcing that its PCIe Gen5 DC SN861 E.1S enterprise-class NVMe SSDs have been certified to support the Nvidia (NVDA) GB200 NVL72 rack-scale system Currently Lower: -- AppLovin (APP) down 3.7% after Goldman Sachs downgraded the stock to Neutral from Buy with a price target of $150, up from $103, citing balanced risk/reward ahead of quarterly results -- Boeing (BA) down 2.0% after announcing on Friday night that it plans to reduce the size of its total workforce by roughly 10% -- Caterpillar (CAT) down 1.8% after Morgan Stanley downgraded shares to Underweight from Equal Weight with a price target of $332, down from $349

Optionshmoptions Posted - 1 month ago

$JSPR I’d rather invest in Horace

OpenOutcrier Posted - 1 month ago

$JSPR (+11.3% pre) Jasper Therapeutics (JSPR) Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria - SI https://ooc.bz/l/44658

BPharmCatalyst Posted - 1 month ago

$TVGN announced plans to share more than $1 billion in revenue potential of its pipeline portfolio beginning the week of October 14, 2024. See More Pre-market Movers 👇 https://www.biopharmcatalyst.com/news/2024/tevogen-tvgn-revenue-announcement-molecular-mtem-liquidation $MTEM $LBPH $IVA $JSPR

topstockalerts Posted - 1 month ago

Pre Market Top Gainers PT2 $INAB $JSPR $IMRN $WHLR $GMM

briefingcom Posted - 1 month ago

Gapping up: $IVA +68.2% $LBPH +51% $RILY +24.3% $JSPR +17.9%

themacromindset Posted - 1 month ago

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria $JSPR

cheating_stock_investor Posted - 1 month ago

$SRRK now $jspr just needs to do their thing.

JB_Research Posted - 1 month ago

$JSPR "is making waves in the biotechnology sector with its innovative approach to treating mast cell-related diseases. Investors and analysts are now closely watching the potential of briquilimab to disrupt the treatment landscape for these underserved patient populations. Jasper has also recently announced plans to expand briquilimab's development into severe asthma, and is actively exploring briquilimab's potential in hematologic conditions" https://www.investing.com/news/company-news/jasper-therapeutics-swot-analysis-briquilimabs-potential-in-mast-cell-diseases-93CH-3638709

LongtermZ94 Posted - 09/30/24

Based on long-term results from the barzolvolimab Ph2 study in CSU presented at the EADV meeting (European Academy of Dermatology and Venereology). While barzo's efficacy continues to look impressive with deepened response over time (from week-12 to week-52), discussions about the updated safety profile have led to volatility for both $CLDX and $JSPR shares in the past few days. Overall, barzo's strong efficacy profile provides further validation for the anti-cKit MoA, while our bullish thesis on $JSPR is that briq's AE profile could potentially offer differentiation due to its unique PK profile and dosing regimen. $JSPR $QQQ

FIREINSP Posted - 09/25/24

$JSPR Back in @$18.10... Easy money...

FIREINSP Posted - 09/25/24

$JSPR Dumped mine @$21. Bought at $8. This is a great trade.

FinJay Posted - 09/23/24

$JSPR https://youtu.be/g2fjhlARQZU?si=nC40OlM8sSOIGzZg

G101SPM Posted - 1 month ago

#SHOWTIME ^^ TD Cowen Chronic Urticaria Summit (September 20) Scheduled to appear: $BPMC, $CLDX, $JSPR, $THRD

Doozio Posted - 2 months ago

$JSPR chop chop huckleberries 🧠⏰♾️